Published on
August 7, 2023
- 11:30 GMT
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 ...
Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care, including the potential for every two- or three-month dosing Initial subcutaneous pharmacokinetic and safety data from healthy volunteers …
Distribution channels:
Technology
...
